Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility in women of reproductive age, and its etiology remains poorly understood. Altered activities of long noncoding RNAs (lncRNAs) have been associated with human diseases and development. However, the roles of lncRNAs are unknown in reproductive medicine. We investigated the potential role of lncRNAs in the pathogenesis of PCOS, using human granulosa cells (GCs) and the KGN cell line. We used microarrays to compare lncRNA expression profiles in GCs from seven patients with PCOS and seven matched women. GC samples were collected during 2014 to 2016 from infertile women in Guangzhou, China. Quantitative real-time polymerase chain reaction was used to measure levels of the lncRNA HCG26 in GCs from 53 patients with PCOS and 50 controls. HCG26 was knocked down with locked nucleic acid GapmeRs in KGN cells to examine its role in cell proliferation, aromatase and follicle-stimulating hormone receptor gene expression, and estradiol production. A total of 862 lncRNA transcripts and 998 messenger RNA transcripts were differentially expressed (greater than or equal to twofold change; P , 0.05) in PCOS GCs compared with those of controls. HCG26 levels were upregulated in patients with PCOS and were associated with antral follicle count. HCG26 knockdown in KGN cells inhibited cell proliferation and cell-cycle progression and increased aromatase gene expression and estradiol production. Our study reports the lncRNA profiles in GCs from patients who have PCOS and those from healthy women and suggests that dysregulated lncRNAs may play vital roles in GC proliferation and steroidogenesis, providing insights into the pathogenesis of PCOS. (Endocrinology 158: 3890-3899, 2017) P olycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility in women of reproductive age and has a prevalence of 5% to 10% worldwide. PCOS manifests as oligo/anovulation, hyperandrogenism, and polycystic ovaries and is associated with infertility, insulin resistance, and increased risk of type 2 diabetes, metabolic syndrome (MetS), cardiovascular disease, and endometrial cancer (1). Compared with healthy women, women with PCOS also have a greater risk of complications during pregnancy, such as ovarian hyperstimulation syndrome, undergoing assisted reproduction treatment, and miscarriage (2). Despite substantial efforts to explore the cause of PCOS in past decades, its etiology remains poorly understood because of its heterogeneous nature. Genetic abnormalities, including gene mutations, epigenetic changes, and noncoding RNAs, are believed to play major roles in the etiology of PCOS (3) (4) (5) .
noncoding RNAs (lncRNAs) (6, 7) . lncRNAs are defined as transcripts .200 nucleotides in length without protein-coding capacity and are emerging as crucial players in various biological processes via diverse mechanisms (8) . lncRNAs can be intergenic (between protein-coding genes; lincRNA), natural antisense, or intronic transcripts or transcribed from promoters and divergent enhancers (9) . Accumulating evidence has shown that lncRNAs are key regulators of development, differentiation, cell proliferation, and apoptosis, and they may play critical roles in diverse human disorders, such as diabetes (10) , cardiovascular disease (11) , neurologic disorders (12) , and tumorigenesis (9) . Although thousands of lncRNAs have been identified, only a few-such as XIST1, NEAT1, and MALAT1-have been functionally characterized; these molecules have been implicated in many biological processes, such as X chromosome inactivation and genomic imprinting, nuclear compartmentalization and architecture, splicing regulation, lncRNA-protein interaction, and chromatin modification (13, 14) .
The recent discovery of lncRNAs has dramatically altered our understanding of human genetics. However, little is known about the roles of lncRNAs in follicular development, steroidogenesis, and PCOS. Neat1 knockout mice stochastically fail to become pregnant despite normal ovulation, and corpus luteum dysfunction may be the primary cause of the decreased fertility (15) . Xu et al. (16) first reported different expression profiles of lncRNAs in cumulus cells (CCs) from oocytes that resulted in good-/poor-quality embryos. Huang et al. (17) determined the lncRNA expression patterns in CCs isolated from patients with PCOS using microarrays and showed that hundreds of lncRNAs were aberrantly expressed in CCs from patients with PCOS compared with those of healthy women.
Although lncRNAs have been identified in human ovarian cells, they have not been screened in further functional and mechanistic studies. CTBP1-AS was identified as an androgen-responsive lncRNA that promotes transcriptional activity of the androgen receptor and the cell cycle for prostate cancer (18) . Recent studies found that CTBP1-AS and SRA in peripheral blood leukocytes were significantly upregulated in women with PCOS compared with controls. A positive correlation was observed between CTBP1-AS expression and total testosterone concentration (19) . The SRA level was also associated with body mass index in patients with PCOS (20) . However, both of these studies are preliminary, and it is unclear whether the lncRNAs present in peripheral blood leukocytes are disease specific in PCOS.
Despite these advances, our current understanding of the biology and disease relevance of lncRNAs in ovaries is still in its infancy. In this study, we first assessed differences between the lncRNA expression profiles of mural granulosa cells (GCs) from preovulatory follicles after controlled ovarian hyperstimulation (COH) from patients with PCOS and from healthy women by microarray. Then, we explored the potential role of the differentially expressed lincRNA human leukocyte antigen complex group 26 (HCG26, Gene ID: 352961) in GC proliferation and steroidogenesis to provide insight into the pathogenesis of PCOS. Because of difficulties in obtaining human GCs in sizable amounts and maintaining primary culture systems, we performed detailed analyses on the molecular and cell biological levels using the ovarian granulosalike tumor cell line KGN, which has steroidogenic activities similar to those of normal GCs and expresses functional follicle-stimulating hormone receptors (FSHRs) (21) .
Materials and Methods
This study was approved by the Institutional Ethics Committee of Nanfang Hospital of Southern Medical University and was carried out in compliance with the Helsinki Declaration. Written informed consent was obtained from all patients.
Subjects
GCs were collected from patients with PCOS and women without PCOS undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment at the Center for Reproductive Medicine, Department of Gynecology and Obstetrics in Nanfang Hospital from March 2014 to June 2016. The PCOS diagnosis was based on the Rotterdam revised criteria (1). The inclusion criteria for control women were as follows: regular menstrual cycles occurring every 25 to 35 days, antral follicle count (AFC) .5, no polycystic ovaries, and no clinical or biochemical evidence of hyperandrogenism. These women entered the IVF/ICSI program for nonovarian indications, which were limited to male factor or tubal disease. All participants were ,37 years old.
The COH protocol for patients undergoing IVF/ICSI treatment consisted of recombinant follicle-stimulating hormone (FSH) (Gonal F; Merck Serono, Modugno, Italy), highly purified FSH (Lishenbao; Livzon, Guangdong, China), and cetrorelix (Cetrotide; Merck Serono, Halle, Germany) stimulation followed by triptorelin (Diphereline; IPSEN, Signes, France) and human chorionic gonadotropin (HCG; Libao Biochemistry Co., Zhuhai, China) administration 34 to 36 hours before oocyte retrieval. GCs were purified by density centrifugation from follicular aspirates collected from women undergoing oocyte retrieval, as previously described (22) (see Supplemental Materials and Methods section).
Cell line
The human GC tumor-derived cell line, KGN, was a gift from Professor Ying-ying Qin at Shandong University. Cells were maintained at 37°C in a humidified incubator containing 5% CO 2 
Cell transfection
KGN cells were transfected at 30% to 40% confluence with 25 nM of locked nucleic acid (LNA) GapmeRs (Exiqon, Vedbaek, Denmark) targeting HCG26 or control LNA GapmeR (GapmeR Ctrl) using Lipofectamine RNAiMax (Life Technologies, Carlsbad, CA) according to the manufacturer's protocol. The efficiencies of RNA knockdown were determined by quantitative real-time PCR (qRT-PCR). The sequences of LNA GapmeRs are described as follows: HCG26 GapmeR-1 (AGCTCATCATGCCTTT), HCG26 GapmeR-2 (CATGAA-GAGGACATTT), and GapmeR Ctrl (AACACGTCTA-TACGC). After 48 hours of transfection, the cells were harvested for further study.
RNA isolation and qRT-PCR
Total RNA from GCs and cultured cells was isolated using RNAiso Plus (TaKaRa, Dalian, China) according to the manufacturer's protocol. Cytoplasmic and nuclear fractions of KGN cells were prepared and collected according to the instructions of the Nuclear/Cytoplasmic Isolation Kit (PARIS Kit, Life Technologies). For measuring mRNAs or lncRNAs, RNA (1 mg) was then reverse transcribed using a PrimeScript RT reagent Kit with gDNA Eraser (TaKaRa) in a 20-mL reaction. qRT-PCR was performed using a SYBR Green PCR kit (TaKaRa) and LightCycler 480 Software (Roche Molecular Biochemicals, Mannheim, Germany). GAPDH was used as an internal control for quantification of target genes. The relative expression of RNAs was calculated using the Equation 2
-DDCT . Primer sequences are listed in Supplemental Tables 1 and 2. RNA fluorescence in situ hybridization RNA fluorescence in situ hybridization (FISH) was performed using lncRNA FISH Probe Mix (RiboBio, Guangzhou, China) according to the manufacturer's protocol. Briefly, cells were rinsed briefly in phosphate-buffered saline (PBS) and then fixed in 4% formaldehyde for 10 minutes at room temperature, followed by cell permeabilization using PBS containing 0.5% Triton X-100 on ice for 5 minutes. Cells were washed in PBS 3 3 5 minutes and incubated in a prehybridization buffer at 37°C for 30 minutes before hybridization. Hybridization was carried out using FISH probes in a moist chamber at 37°C for 12 to 16 hours in the dark. Then the cells were washed and mounted for detection. Imaging was performed immediately using an FV10i confocal laser microscope (Olympus, Tokyo, Japan).
Cell counting kit-8 assays, ethynyl-2 0 -deoxyuridine assays, flow cytometry, and western blot analyses
Cell counting kit-8 assays, ethynyl-2 0 -deoxyuridine assays, flow cytometry, and western blot analyses were performed as previously described (23) and as detailed in the Supplemental Materials and Methods section.
Measurement of estradiol
KGN cells (2 3 10 4 ) were seeded in 24-well plates in serumfree medium and treated with androstenedione (100 nM; Sigma, Kansas City, MO) for 24 hours after HCG26 knockdown. Following the specified treatments, culture medium was assayed immediately or stored at 280°C until analysis. Estradiol (E 2 ) accumulation in conditioned medium was measured using a chemiluminescence kit (Roche).
Statistical analyses
Data were analyzed using either a Student t test for quantitative data with a Gaussian distribution or a Mann-Whitney U test for data with a non-Gaussian distribution, and the results were expressed as the mean 6 standard deviation of at least three independent experiments. We used SPSS 16.0 software (SPSS Inc., Chicago, IL) and GraphPad Prism 5 (GraphPad, Inc., La Jolla, CA). Correlations between lincRNA HCG26 and clinical indexes of patients were analyzed by Pearson or Spearman rank correlation. P , 0.05 was considered statistically significant.
Results

Subject characteristics
A total of 117 subjects (60 women with PCOS and 57 healthy women) were included in this study (seven patients with PCOS and seven controls for microarray analysis and the others for qRT-PCR analysis). No significant differences were observed regarding age or body mass index between the PCOS and control groups from lncRNA microarray (P = 0.812 and P = 0.095, respectively) (Supplemental Table 3 ).
Profiles of differentially expressed lncRNAs and mRNAs
To identify transcripts potentially involved in the etiology of PCOS, we assessed the lncRNA and mRNA expression profiles by microarray analysis. Differentially expressed lncRNAs were identified using scatterplot and volcano plot filtering (Supplemental Fig. 1) . A total of 862 lncRNA transcripts were differentially expressed in the GCs from the PCOS group compared with those from the non-PCOS group, with 692 upregulated and 170 downregulated (Fig. 1A) . Among the dysregulated lncRNA transcripts, ENST00000533082 (FC = 64.89) was the most significantly upregulated lncRNA, whereas ENST00000448179 (FC = 231.46) was the most significantly downregulated lncRNA (Table 1 ). In addition, 905 upregulated mRNAs and 93 downregulated mRNAs were identified. The microarray 
qRT-PCR validation of lncRNAs and mRNAs
To validate the results of the microarray, we analyzed the differentially expressed transcripts (12 lncRNAs and eight mRNAs) by qRT-PCR in GCs from 10 patients with PCOS and 10 matched women without PCOS. These RNA transcripts were chosen on the basis of RNA length (,3500 nucleotides), group raw intensity (.300), and FC ($2.0). The qRT-PCR analyses confirmed the microarray findings. All 12 lncRNAs (ENST00000457602, TCONS_00003974, TCONS_00019181, ENST00000508713, ENST00000510619, NR_028308, TCONS_00028340, ENST00000556030, ENST00000556578, ENST00000499653, HCG26, and NR_040662) and eight mRNAs (FFAR2, CH25H, SAMSN1, AQP9, BCL2A1, S100A8, PREX1, and ACSL1) were differentially expressed with the same trend (upregulated) and reached statistical significance (P , 0.05 for each RNA) (Fig. 1B and 1C) . We focused predominantly on upregulated lncRNAs because this set can be used more readily than downregulated lncRNAs as early diagnosis markers or therapeutic targets.
lincRNA HCG26 was upregulated in PCOS GCs lincRNA HCG26 was one of the upregulated lncRNAs and was expressed in both primary GCs and KGN cells. To further validate the increase in HCG26, we analyzed its expression by qRT-PCR in a total of 103 GC samples from 53 patients with PCOS and 50 matched controls. The characteristics of the patients with PCOS and controls are shown in Supplemental Table 4 . We found that HCG26 levels were significantly higher in PCOS GCs than in non-PCOS GCs (P , 0.001) (Fig. 2A) .
To determine whether HCG26 expression levels were related to hormonal and clinical features of the women undergoing assisted reproduction, we analyzed the associations between HCG26 and clinical characteristics in the 103 patients mentioned previously. As shown in Supplemental Table 5 , statistical analyses indicated significant correlations between HCG26 expression and AFC (r = 0.313; P = 0.001), number of follicles aspirated (r = 0.268; P = 0.006), starting gonadotropin (Gn) dose (r = 20.238; P = 0.016), and total Gn dose (r = 20.233; P = 0.018). However, no association between HCG26 and other clinical characteristics was observed.
HCG26 knockdown inhibited GC proliferation and cell-cycle progression in vitro
To investigate the biological significance of HCG26 expression in GCs, we next performed a loss-of-function study in KGN cells. RNA-FISH was applied to visualize the cellular localization of HCG26 in KGN cells. HCG26 predominantly localized to nuclear regions (Fig. 2B) . Furthermore, RNA from nuclear and cytoplasmic fractions was analyzed by qRT-PCR, revealing that HCG26 was primarily distributed in the nucleus (Fig. 2C) . Because small interfering RNAs may not target nuclear RNAs (24), we silenced HCG26 expression with LNA GapmeRs, which are single-stranded oligonucleotides that consist of a DNA stretch flanked by LNA nucleotides. GapmeR treatment resulted in a reduction in HCG26 level compared with that of the control GapmeR (Fig. 2D) .
To assess the role of HCG26 in cell proliferation, we performed a cell counting kit-8 assay and an ethynyl-2 0 -deoxyuridine assay. The results showed that HCG26 knockdown significantly inhibited cell viability in KGN cells (Fig. 2E-2G) . Next, to elucidate the mechanism by which HCG26 affected cell proliferation, we analyzed differences in cell-cycle distributions after HCG26 knockdown by flow cytometry analysis. The results of HCG26-GapmeR transfection for 48 hours showed that HCG26 knockdown increased the percentage of cells in the G 0 /G 1 phase and decreased the percentage of cells in the S and G 2 /M phases compared with control cells (Fig. 2I and 2J) . Consistent with the flow cytometry results, the expression of a G 1 /S-phase checkpoint protein, cyclin A, was substantially decreased in cells when HCG26 was silenced. Cyclin B1, a G 2 /M-phase2specific protein, showed similar results (Fig. 2H) . These data indicate that HCG26 knockdown inhibited GC proliferation by blocking cell-cycle progression.
To determine whether the effects of HCG26 on cell proliferation are associated with cell apoptosis, we performed flow cytometry assays. The results showed that KGN cells transfected with HCG26 GapmeRs had apoptosis rates similar to those of control cells (Supplemental Fig. 2 ). These data demonstrate that HCG26 may not affect the apoptosis of GCs.
HCG26 knockdown promoted aromatase gene expression and E 2 production
To investigate the role of HCG26 in steroidogenesis, we treated KGN cells for 24 hours with androstenedione (100 nM) after HCG26-GapmeR transfection for 48 hours, and the relative aromatase gene (CYP19A1) level was determined by qRT-PCR. We found that silencing of HCG26 significantly promoted the mRNA level of aromatase (Fig. 3A) . Moreover, HCG26 knockdown significantly enhanced E 2 accumulation (Fig. 3C) . However, HCG26 knockdown had no effect on FSHR mRNA levels (Fig. 3B) . These data suggest that HCG26 knockdown promoted aromatase gene expression and E 2 production and that FSHR may not be involved.
Androstenedione and FSH had no effects on the level of HCG26
Given the hyperandrogenism and the required supraphysiologic stimulation with Gns as well as the difference in dosing required between PCOS cases and controls, KGN cells were cultured for 48 hours in the presence of vehicle control, androstenedione (100 nM), or combined FSH (0.2 IU/mL) and androstenedione to confirm the impact of androgen and FSH on HCG26 expression. As shown in Supplemental Fig. 3 , treatment with androstenedione or combined FSH and androstenedione did not alter HCG26 levels in KGN cells in vitro.
Effects of insulin on HCG26 expression in KGN cells
Insulin resistance in classic and nonclassic insulin target tissues has been shown to contribute to PCOS pathophysiology (25) . Cells were treated with recombinant human insulin (Sigma) at concentrations of 0, 1, 10, and 100 ng/mL for 24 hours to test the expression of HCG26 ( Supplemental Fig. 4) . The concentration of insulin (10 ng/mL) was equivalent to postprandial levels and was within the range expected in the serum of insulinresistant women (26) . KGN cells incubated with insulin for 24 hours showed no significant differences in HCG26 expression compared with controls (P . 0.05).
Discussion
In the current study, we first assessed genome-wide lncRNA expression profiles by microarray in the GCs of women with and without PCOS. We found that 862 lncRNAs and 998 mRNAs were dysregulated in PCOS GCs. Differentially expressed transcripts (12 lncRNAs and eight mRNAs) were analyzed by qRT-PCR, and the analysis confirmed the microarray findings. We reported that lincRNA HCG26 was upregulated in women with PCOS and was associated with AFC and number of oocytes aspirated. HCG26 was predominantly localized in the nuclei of human GCs. Decreased cell viability and significant G1/S arrest were observed in HCG26-knockdown KGN cells, but no effects were found on cellular apoptosis, suggesting that HCG26 knockdown inhibited cell proliferation by restraining cell-cycle progression. We also found that HCG26 knockdown promoted aromatase gene expression and E 2 production, without effects on FSHR mRNA level. These findings indicate that the differentially expressed lncRNAs are involved in GC proliferation and steroidogenesis, contributing to the pathogenesis of PCOS.
PCOS is believed to be caused by genetic abnormalities, and research in the past decades has focused primarily on the mRNA transcriptome. Chen et al. (27) identified 11 susceptibility loci associated with PCOS in the Han Chinese population by genome-wide association studies, and the candidate genes at these associated loci were related to hormones, organ growth, cytokinesis, and cell division (3). Diabetes mellitus and cardiovascular genes, such as LRRK2, AQP9, TXNIP, and ITGAX, were reported to be upregulated in women with PCOS (22) , which was consistent with our microarray findings. Wang et al. (4) reported that approximately 3% of sites were differentially methylated and 650 differential transcripts were observed between PCOS ovaries and normal ovaries. However, because of the heterogeneity of PCOS and the complexity of gene regulatory networks, the susceptibility genes for PCOS remain poorly understood.
Recent studies revealed that approximately 10-to 20-fold more genomic sequences are transcribed to lncRNAs than to protein coding RNAs, and these lncRNAs have attracted intense scientific interest (8) . Previous microarray analyses have shown that lncRNAs may be involved in the development of preeclampsia (28), premature preterm membrane rupture (29) , and endometriosis (30) . Yerushalmi et al. (31) first found lncRNAs expressed in CCs and showed that they may participate in the maturation of cumulus oocyte complexes and cumulus expansion. Recently, Huang et al. (17) found that clusters of lncRNAs were aberrantly expressed (620 were upregulated, and three were downregulated) in CCs of patients with PCOS compared with those of healthy women, suggesting that the differentially expressed lncRNAs may contribute to the occurrence of PCOS and may affect oocyte development. However, to the best of our knowledge, no study has investigated the lncRNA profiles in GCs of women with PCOS. In this study, we first showed that 862 lncRNAs were differentially expressed by an absolute difference of greater than or equal to twofold in PCOS GCs. The differentially expressed lncRNAs isolated in this study were not identical to those published in the previous report (17) , which may be due to the diversity in ovarian cell types, COH protocols, and gene chips. lncRNAs are expressed in a tissue-specific and developmentally regulated manner, and previous mRNA expression profiles of CCs and GCs in the preovulatory follicle after COH have shown two cell populations with differentiated functions (32, 33) .
PCOS is associated with a wide range of endocrine and metabolic abnormalities, including glucose intolerance, hyperinsulinemia, dyslipidemia, and obesity, which are also closely linked to MetS (34) . A previous genome-wide association study showed that the single-nucleotide polymorphism of HCG26 rs3099844 was associated with MetS (35) . This study identified the association between PCOS and HCG26. HCG26 was upregulated in PCOS GCs, and its expression was associated with the number of antral follicles. Knockdown of HCG26 led to decreased cell viability and restrained cell-cycle progression in KGN cells. Although many reports have shown that lncRNAs can regulate the proliferation of tumor cells (23, 36, 37) , few studies have examined the involvement of lncRNAs in the regulation of ovarian cells. lncRNAs enhance cell proliferation via diverse mechanisms, including promoting cell-cycle progression, inhibiting cell apoptosis (23), regulating cell metabolism (38) , and pairing with a specific gene promoter region (37) . In this study, we found that HCG26 knockdown inhibited the cellcycle progression in GCs but did not affect cell apoptosis. Evidence has indicated that the increase in GC proliferation is associated with PCOS (39, 40) . The expression of HCG26 was significantly higher in the PCOS group than that in the control group, suggesting that HCG26 may affect cell proliferation in GCs and contribute to excess antral follicles.
Furthermore, we found that silencing of HCG26 led to increased aromatase gene expression and enhanced E 2 production. Androstenedione and FSH treatment had no effect on the expression of HCG26. Nevertheless, we cannot exclude the possibility that FSH may alter lncRNA expression in vivo. Aromatase, encoded by the CYP19A1 gene, acts through the aromatization of testosterone and androstenedione to maintain the homeostatic balance between androgens and estrogens in both sexes. CYP19A1 has been reported to play an important role in the development of PCOS. The GCs obtained from PCOS follicles expressed minimal aromatase, and reduced aromatase activity is reported to contribute to increased testosterone level (41) . Folliculogenesis is affected by high concentrations of androgens. Androgen treatment increased the number of growing preantral and small antral follicles, and granulosa and thecal cell proliferation was significantly increased in these follicles (42) . The intraovarian hyperandrogenism in PCOS promotes early follicular growth, leading to a 2-to 5-mm follicle excess; the excess selectable follicles then inhibit the selection process and the differentiation of GCs (43) . Taken together, these data suggest that abnormal HCG26 expression may interfere with aromatase expression and E 2 production in the ovary, implying a potential contributing factor for the accumulation of androgen observed in PCOS. However, whether the dysregulation of lncRNA expression in PCOS is secondary to its hormonal and/or metabolic abnormalities requires investigation.
Most recent studies have shown that lncRNAs localize primarily to the nucleus, and we found that HCG26 was also predominantly distributed in the nucleus. The molecular mechanisms by which HCG26 is associated with cell proliferation and steroidogenesis remain unclear. However, evidence thus far indicates that most nuclear lncRNAs function by binding to chromatin-modifying factors, heterogeneous nuclear ribonucleoproteins, or transcription factors (13) . Additional studies are necessary to define the precise molecular function of HCG26.
A few limitations persist when interpreting the present findings. First, the GCs used for assessing the lncRNA expression profiles were obtained from preovulatory follicles after Gn stimulation. The hormonal treatment used in IVF may alter the gene expression profiles. Moreover, these cells may not behave in the same way as GCs from small antral follicles. Thus, assessing the expression patterns of unstimulated, different-sized follicles in patients with PCOS would provide a more comprehensive view of the lncRNAs involved in the etiology of the syndrome. Second, the isolation of primary cells inevitably causes contamination with other tissues, such as blood cells, so it is necessary to validate the biological functions of lncRNAs in GC-derived cell lines such as KGN and SVOG cells. Finally, given the multifaceted nature of PCOS, a single genetic signal is not sufficient to account for the considerable genetic susceptibility for this syndrome; therefore, future studies aimed at the interaction of the genetic network, including DNA, RNA, and proteins, will be of great interest.
In summary, we identified a subset of lncRNAs that were differentially expressed in GCs from patients with PCOS and those from matched healthy women. We also demonstrated that lincRNA HCG26 was upregulated in patients with PCOS and was associated with the number of antral follicles. HCG26 knockdown inhibited cell proliferation and increased aromatase expression and E 2 production, suggesting that HCG26 may play an important role in PCOS progression. Future studies focusing on more dysregulated lncRNAs in patients with PCOS could further elucidate the complexities of this syndrome and help develop novel strategies for PCOS therapy.
